“`html
Post-transaction pro forma metrics: Authorized shares 100,000,000, Issued & outstanding 80,500,000, Restricted shares 77,973,000, Unrestricted float 2,527,000, and fully diluted float 7,777,000 (including 5,250,000 restricted shares set to lose restrictions in Q1 2026). LMMY intends to pursue a NASDAQ uplisting; MAJI may retain shares near-term and evaluate a share dividend in 2026.
Metriche pro forma post-transazione: Azioni autorizzate 100.000.000, Azioni emesse e in circolazione 80.500.000, Azioni vincolate 77.973.000, float non vincolato 2.527.000, e float completamente diluito 7.777.000 (incluso 5.250.000 azioni vincolate che perderanno le restrizioni nel Q1 2026). LMMY intende procedere con una quotazione NASDAQ; MAJI potrebbe mantenere azioni a breve termine e valutare un dividendo azionario nel 2026.
Métricas pro forma posteriores a la transacción: Acciones autorizadas 100,000,000, Emitidas y en circulación 80,500,000, acciones restringidas 77,973,000, float no restringido 2,527,000, y float totalmente diluido 7,777,000 (incluyendo 5,250,000 acciones restringidas que perderán las restricciones en Q1 2026). LMMY planea buscar una cotización adicional en NASDAQ; MAJI podría retener acciones a corto plazo y evaluar un dividendo de acciones en 2026.
거래 후 프로 포르마 지표: 허용 주식 100,000,000, 발행 및 유통 80,500,000, 제한 주식 77,973,000, 제한 없는 유통주 2,527,000, 그리고 완전 희석 유통주 7,777,000 (포함된 5,250,000의 제한 주식은 2026년 1분기에 제한이 해제될 예정). LMMY는 NASDAQ 상장을 추진할 예정이며; MAJI는 단기적으로 주식을 보유할 수 있고 2026년에 주식 배당을 평가할 수 있습니다.
Indices pro forma post-transaction : Actions autorisées 100 000 000, Émis et en circulation 80 500 000, Actions restreintes 77 973 000, Float non restreint 2 527 000, et float entièrement dilué 7 777 000 (y compris 5 250 000 actions restreintes qui perdront leurs restrictions au 1er trimestre 2026). LMMY envisage une hausse de cote NASDAQ; MAJI pourrait conserver des actions à court terme et évaluer un dividende en actions en 2026.
Pro-forma-Metriken nach der Transaktion: Genehmigte Aktien 100.000.000, Ausgegeben & im Umlauf 80.500.000, Eingeschränkte Aktien 77.973.000, Unbeschränkter Streubesitz 2.527.000, und vollständig verwässerter Streubesitz 7.777.000 (einschließlich 5.250.000 eingeschränkter Aktien, die im Q1 2026 ihre Beschränkungen verlieren). LMMY beabsichtigt, ein NASDAQ-Uplisting voranzutreiben; MAJI könnte kurzfristig Aktien halten und 2026 eine Aktiendividende prüfen.
مقاييس ما بعد الصفقة بشكل برو فورت: الأسهم المصرّح بها 100,000,000، المصدرة وفي التداول 80,500,000، الأسهم المقيدة 77,973,000، التداول غير المقيد 2,527,000، والتداول المخفف بشكل كامل 7,777,000 (بما في ذلك 5,250,000 من الأسهم المقيدة التي ستفقد القيود في الربع الأول 2026). تعتزم LMMY متابعة الإدراج في NASDAQ؛ قد تحتفظ MAJI بالأسهم على المدى القريب وتقيّم توزيع أسهم في 2026.
Positive
- MAJI obtained approximately 51% of LMMY common stock, securing control
- Post-deal Issued & outstanding 80,500,000 shares provides clear capital structure
- Transaction places Exousia AI onto an SEC-reporting platform (LMMY) for audited access
- Agreement includes annual licensing fees and ongoing royalties to MAJI
Negative
- Current unrestricted float is only 2,527,000 shares, limiting near-term liquidity
- 77,973,000 restricted shares represent a highly restricted capital base
- 5,250,000 restricted shares scheduled to unlock in Q1 2026, increasing available supply
- Initial board/management of LMMY is concentrated: Matthew Dwyer as sole Officer and Director
ORLANDO, FLORIDA – Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology firm specializing in exosome-based drug delivery, announced a significant strategic move on Monday, November 17, 2025. The company has secured a controlling interest in LAMY (OTCID:LMMY), an SEC-reporting entity, through an all-stock transaction. Exousia Pro exchanged its subsidiary, Exousia AI, for approximately 51% of LAMY’s restricted common stock, effectively positioning MAJI as the controlling shareholder. Alongside this acquisition, MAJI and LAMY have entered into a licensing agreement, structured to provide MAJI with annual licensing fees and royalties tied to LAMY’s commercialization of its exosome technology.
The strategic rationale behind the deal centers around accelerating growth for Exousia AI independently. By integrating Exousia AI into an SEC-reporting platform, the company gains enhanced credibility, facilitating broader partnerships, collaborations, and access to capital markets previously unavailable. Furthermore, the transaction is designed to be non-dilutive to MAJI shareholders, allowing Exousia AI to raise its own expansion capital. Rebranding also plays a role, as the move allows Exousia AI to distance itself from MAJI’s former association with “Marijuana Inc.,” potentially improving its ability to attract talent and institutional investment.
MAJI benefits from the transaction through a number of avenues. Aside from the substantial equity stake in LMMY, MAJI secures a recurring revenue stream via the licensing agreement, aligning its financial interests with the future success of Exousia AI. The SEC reporting status of LMMY provides a transparent pathway for valuation of its technology, particularly concerning Glioblastoma and other cancer treatments, which could positively impact MAJI shareholders. More significantly, LAMY intends to pursue a NASDAQ uplisting, which would validate the technology and likely enhance the value of MAJI’s equity stake.
From a corporate finance perspective, the deal showcases an intricate approach to unlocking value within different divisions of the company. By offloading Exousia AI onto a new platform, Exousia Pro seeks to achieve strategic operational objectives, while retaining significant equity in the long-term success of the transferred technology. This action enables MAJI to pursue its own corporate objectives and to consider a share dividend in 2026, according to company statements.
The post-merger capital structure of LMMY presents a mixed picture. While the authorized shares stand at 100,000,000 and issued and outstanding shares total 80,500,000, a substantial 77,973,000 shares are restricted. This leaves a comparatively small unrestricted float of 2,527,000, suggesting potential volatility in the near-term due to limited liquidity. Notably, 5,250,000 restricted shares are slated to become unrestricted in Q1 2026, which could increase the float and potentially dilute the value per share, requiring careful market management.
Matthew Dwyer, President of Exousia Pro, emphasized in a statement that the transaction helps unlock Exousia AI’s full potential by providing an SEC-reporting platform that positions the company to secure capital necessary for accelerating the development of critical cancer treatments. “We are convinced that this powerful structure places MAJI and its shareholders into a significantly better position from which to benefit from Exousia AI’s anticipated future success, without enduring any further dilution.”
The market’s long term reception will hinge on several factors. These include the speed at which LMMY can achieve the NASDAQ uplisting, the market validity of the exosome technology and the commercial performance of Exousia AI’s Glioblastoma and cancer treatments. The dilution effect of the restricted shares unlocking in Q1 2026 remains another key uncertainty.
About Exousia Pro, Inc.
Exousia Pro, Inc. (EXO) specializes in the development and manufacturing of mammalian and plant-derived exosomes. Using proprietary technologies that focus on nucleic acid loading and targeted delivery to tissues and cells, Exousia Pro aims to improve patient responsiveness to anti-cancer therapies through its work on cancer stem cells.
Disclaimer: Forward-looking statements carry inherent risks and uncertainties. Actual results may differ from projections due to various factors beyond the control of Exousia Pro, Inc.
FAQ
What did Exousia Pro (MAJI) announce on November 17, 2025 regarding LMMY?
MAJI announced an all-stock exchange transferring Exousia AI to LMMY in return for ~51% of LMMY restricted common stock, making MAJI the controlling shareholder.
How many LMMY shares are unrestricted after the transaction and what does that mean for liquidity?
The post-transaction unrestricted float is 2,527,000 shares, indicating relatively limited immediate public liquidity.
When will restricted LMMY shares become available to the market?
The release notes 5,250,000 restricted shares are set to lose restrictions in Q1 2026.
Does MAJI retain economic interest in Exousia AI after the transaction?
Yes; MAJI holds ~51% of LMMY, retains licensing and royalty arrangements, and plans to retain shares near-term.
What are the key pro forma capital-structure figures for LMMY after the deal?
Key figures: Authorized 100,000,000; Issued & outstanding 80,500,000; Restricted 77,973,000; Fully diluted 7,777,000.
Will LMMY pursue a senior exchange listing and how does that affect MAJI?
LMMY intends to begin pursuing a NASDAQ uplisting, which MAJI says could validate the technology and enhance MAJI’s equity stake value.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/13018.html
